Genome editing or small molecule inhibition of KMT5A in CAR-T cells enhances antitumor immunity
Our findings establish <i>KMT5A</i> as an epigenetic regulator that impairs CD8+T cell function. These findings demonstrate that genetic or pharmacological (eg, UNC0379) targeting of <i>KMT5A</i> in CD8+T cells represents a viable therapeutic strategy to augment effector functions and improve adoptive T-cell therapies, particularly CAR-T cells, for solid tumors.
Authors
- Bing Du (ORCID: https://orcid.org/0000-0002-5402-6527)
- Na Zhang
- Yuxuan Wu (ORCID: https://orcid.org/0000-0002-9155-9883)
- Guolong Liu
- Xiaoling Tian
- Qiudao Wang
- Yanting Shen (ORCID: https://orcid.org/0000-0001-8129-0844)
Institutions
- ShanghaiTech University (CN)
- Shanghai Cell Therapy Research Institute (CN)
- East China Normal University (CN)
Publication Details
- Journal
- Journal for ImmunoTherapy of Cancer
- Published
- 2025-09-01
- DOI
- https://doi.org/10.1136/jitc-2025-012160
- Citations
- 1
- Primary Topic
- CAR-T cell therapy research
- Type
- article
- Field-Weighted Citation Impact
- 1.05
Funders
- National Natural Science Foundation of China
- East China Normal University